Project Number 5R42AG062063-03 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease. Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) r. Multi-target Researcher and Organization Principal Investigator MULLAN, MICHAEL Principal Investigator First Name MICHAEL Principal Investigator Last Name MULLAN Awardee Organization ARCHER PHARMACEUTICALS, INC. Awardee State Florida Contact PI Country United States Project Detail Funding Opportunity Announcement PAS-18-188: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) FY Overall Cost $699,018 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MARTIN, ZANE
